N-(2,4,6-trimethylphenyl)-3-bicyclo[2.2.1]heptanecarboxamide profile

Cross-References

ID Source	ID
PubMed CID	3111211
CHEMBL ID	1703636
CHEBI ID	91537
SCHEMBL ID	2231882

Synonyms (44)

Synonym
OPREA1_569412
VU0448090-1
ml213
smr000514557
OPREA1_116161
MLS001211210
bicyclo[2.2.1]heptane-2-carboxylic acid (2,4,6-trimethyl-phenyl)-amide
n-(2,4,6-trimethylphenyl)bicyclo[2.2.1]heptane-2-carboxamide
STK373915
cid3111211
JHICC03001
n-(2,4,6-trimethylphenyl)bicyclo[2.2.1]heptane-3-carboxamide
AKOS003240435
MLS003370512
HMS2821C12
n-(2,4,6-trimethylphenyl)-bicyclo[2.2.1]heptane-2-carboxamide
489402-47-3
REGID_FOR_CID_3111211
S6553
AKOS022071351
gtpl7665
n-(2,4,6-trimethylphenyl)bicyclo[2.2.1]heptane-6-carboxamide
ml-213
ml 213
SCHEMBL2231882
CHEMBL1703636 ,
HB1064
n-(2,4,6-trimethylphenyl)-bicyclo[2 .2.1]heptane-2-carboxamide
n-mesitylbicyclo[2.2.1]heptane-2-carboxamide
DTXSID80389360
CHEBI:91537
HY-101843
CS-6933
ml-213(cid-3111211)
BCP06878
cid 3111211
EX-A2551
Q27087011
bicyclo[2.2.1]heptane-2-carboxylic acid (2,4,6-trimethyl phenyl)amide
AS-16685
cid-3111211
bdbm50465775
(1s,4r)-n-mesitylbicyclo[2.2.1]heptane-2-carboxamide
AC-36129

Class	Description
monoterpenoid	Any terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	37.9330	0.0072	15.7588	89.3584	AID588342
ATAD5 protein, partial	Homo sapiens (human)	Potency	8.1961	0.0041	10.8903	31.5287	AID504467
TDP1 protein	Homo sapiens (human)	Potency	29.0929	0.0008	11.3822	44.6684	AID686978
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	7.9433	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	7.9433	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	7.9433	0.1585	5.2879	12.5893	AID540303
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
potassium voltage-gated channel subfamily KQT member 1 isoform 1	Homo sapiens (human)	EC50 (µMol)	31.9263	0.5480	11.0648	31.9263	AID493042
potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)	EC50 (µMol)	31.9263	31.9263	31.9263	31.9263	AID493042
potassium voltage-gated channel subfamily KQT member 4 isoform a	Homo sapiens (human)	EC50 (µMol)	1.4563	0.5125	1.4563	2.4000	AID493043; AID504416
potassium voltage-gated channel subfamily KQT member 3	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.3664	0.3664	0.3664	0.3664	AID493039
potassium voltage-gated channel subfamily KQT member 2	Rattus norvegicus (Norway rat)	EC50 (µMol)	4.5716	0.2300	61.1402	554.6400	AID493037; AID493038; AID493039; AID493042; AID493043; AID504416
Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)	EC50 (µMol)	0.2700	0.0400	1.5208	4.3800	AID1414246; AID1414248
Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)	EC50 (µMol)	0.0400	0.0400	1.3227	4.3800	AID1414246
Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)	EC50 (µMol)	1.6000	1.6000	2.9700	5.9000	AID1414249
Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)	EC50 (µMol)	0.5000	0.5000	1.7875	3.4500	AID1414248
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)	Activity	0.0400	0.0400	0.2733	0.4600	AID1414250
Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)	Activity	0.0400	0.0400	0.2733	0.4600	AID1414250
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
protein targeting	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
protein import into nucleus	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
exocytosis	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
endocytosis	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
chemical synaptic transmission	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
sensory perception of sound	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
gene expression	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
response to auditory stimulus	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
response to organic cyclic compound	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
neuron remodeling	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
neuronal action potential	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
nerve development	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
psychomotor behavior	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
regulation of synaptic plasticity	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
neuron apoptotic process	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
mitochondrial depolarization	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
membrane hyperpolarization	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
cellular response to calcium ion	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
apoptosome assembly	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
excitatory chemical synaptic transmission	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
inhibitory chemical synaptic transmission	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
action potential initiation	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
regulation of action potential firing threshold	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
substantia propria of cornea development	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
chemical synaptic transmission	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
nervous system development	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
action potential	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
potassium ion transport	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
sensory perception of sound	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
inner ear morphogenesis	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
calmodulin binding	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
calmodulin binding	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
ankyrin binding	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
potassium channel activity	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
mitochondrion	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
node of Ranvier	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
axon initial segment	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
synapse	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
node of Ranvier	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
axon initial segment	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
synapse	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
membrane	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
basal plasma membrane	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)
clathrin coat	Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay ID	Title	Year	Journal	Article
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1414246	Activation of human Kv7.2/7.3 by patch clamp method	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	Novel K
AID1414248	Activation of human Kv7.3/7.5 by patch clamp method	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	Novel K
AID1414250	Activation of human wild type Kv7.2/7.3 expressed in CHO cells assessed as 86Rb efflux at 0.001 to 100 uM after 10 mins by microbeta liquid scintillation counting analysis	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	Novel K
AID1414251	Activation of human Kv7.2 W236L mutant/Kv7.3 W265L mutant expressed in CHO cells assessed as 86Rb efflux at 0.001 to 100 uM after 10 mins by microbeta liquid scintillation counting analysis	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	Novel K
AID1414264	Activation of human Kv7.2/7.3 assessed as difference in G-V midpoint between pre-compound and post-compound conditions at 3 uM at -90 mV holding potential by QPatch method	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	Novel K
AID1414249	Activation of human Kv7.4 by patch clamp method	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	Novel K
AID1346699	Human Kv7.4 (Voltage-gated potassium channels)	2011	ACS chemical neuroscience, Oct-19, Volume: 2, Issue:10	Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (14.29)	29.6817
2010's	5 (71.43)	24.3611
2020's	1 (14.29)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
ezogabine ezogabine: structure in first source. ezogabine : A substituted aniline that is benzene-1,2,4-triamine bearing ethoxycarbonyl and 4-fluorobenzyl substituents at positions N-1 and N-4 respectively. An anticonvulsant used to treat seizures associated with epilepsy in adults.	2.17	1	0	carbamate ester; organofluorine compound; secondary amino compound; substituted aniline	anticonvulsant; potassium channel modulator
ica 27243 N-(6-Chloropyridin-3-yl)-3,4-difluorobenzamide: a KCNQ2/3 channel activator; structure in first source	2.17	1	0

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Aura [description not available]	2.17	1
Absence Seizure [description not available]	2.17	1
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	2.17	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2.17	1
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	2.17	1

N-(2,4,6-trimethylphenyl)-3-bicyclo[2.2.1]heptanecarboxamide

Cross-References

Synonyms (44)

Drug Classes (1)

Protein Targets (15)

Potency Measurements

Activation Measurements

Other Measurements

Biological Processes (30)

Molecular Functions (5)

Ceullar Components (10)

Bioassays (19)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.29

Study Types

N-(2,4,6-trimethylphenyl)-3-bicyclo[2.2.1]heptanecarboxamide

Cross-References

Synonyms (44)

Drug Classes (1)

Protein Targets (15)

Potency Measurements

Activation Measurements

Other Measurements

Biological Processes (30)

Molecular Functions (5)

Ceullar Components (10)

Bioassays (19)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.29

Study Types

Related Drugs (2)

Related Conditions (7)